How to Know When to Sell a Stock: Monitor the Thesis, Not the Price

Most investors watch the wrong thing. They open their brokerage app, see a stock down 8%, and feel their conviction wobble. They see it up 12% and feel smart. In both cases they're reacting to price — which, on any given day, tells you almost nothing about whether the business you bought is still doing what you expected it to do.

The price of a stock and the health of the underlying business are only loosely connected in the short run. A great company can fall 40% because the whole market de-rated, not because anything changed inside it. A mediocre one can rise for a year on nothing but momentum. If you use price as your monitoring signal, you'll sell your winners in a panic and hold your mistakes out of hope.

There's a better way to decide when to sell, and it starts before you ever buy.

A stock thesis is a set of claims you can prove wrong

When you buy a stock, you're making an argument. It might be: "This company's core market is growing 15% a year, it's taking share, and margins will expand as it scales." That's a thesis. And a good thesis has a useful property — it's falsifiable. Each claim in it can turn out to be true or false, and you can check.

The problem is that most people never write the argument down. They hold a vague, warm feeling about a company instead of a set of specific claims. And a warm feeling can't be proven wrong — it just quietly adapts to whatever the stock does next. That's how investors end up "still believing" in a business whose numbers stopped supporting the story two years ago.

So the first job of monitoring is to turn your thesis into a short list of testable statements. For a company you're researching, that might look like:

• Core procedure or unit volume keeps growing at a double-digit rate.
• The company is still winning new customers faster than it's losing them.
• Gross margin holds or expands rather than eroding.
• The balance sheet stays clean — no surprise leverage, no cash burn.

Notice that none of these mention the share price. That's the point.

Pre-register the KPIs — and the thresholds — before you buy

Here's the discipline that separates careful investors from the rest: decide in advance which specific numbers would confirm your thesis, which would break it, and at what level.

This matters because of a very human failure called motivated reasoning. Once you own something, your brain starts working for the position. A number that would have worried you before you bought suddenly gets explained away. "Growth slowed to 12%, but that's just a tough comparison quarter." Maybe it is. But if you'd written down beforehand that "growth below 13% for two straight quarters breaks the thesis," you'd be forced to actually confront it instead of rationalizing.

Pre-registering does two things. It picks the metrics that genuinely matter for your argument — not the ones the financial media happens to be excited about — and it sets the thresholds while you're still thinking clearly, before you have skin in the game distorting your judgment.

A pre-registered monitoring plan might read:

Thesis claim: Volume growth stays double-digit. KPI: Year-over-year procedure growth. Confirm: ≥13%. Watch: 10–13%. Break: <10% for two consecutive quarters.

Do that for each claim, and monitoring stops being an anxious daily ritual and becomes a quarterly checklist.

Know where each number actually lives

A subtle but important point: the KPI you care about often isn't in the headline you'll read.

Take a company like Intuitive Surgical (ISRG), the robotic-surgery maker. Its quarterly earnings press release gives you the crowd-pleasing figures: worldwide procedure growth, how many surgical systems it placed, how big the installed base has grown. That's useful — it speaks directly to a volume-growth thesis.

But the press release is a curated document. Management chooses what to highlight. The deeper accounting signals — the ones that reveal whether the quality of that growth is holding up — usually don't appear until the full quarterly report, the 10-Q, which is filed separately with regulators and can land days or even weeks after the earnings headline. Line items buried in the cash flow statement and the notes often tell you more about a business's trajectory than the number that made the news.

So part of a monitoring plan is knowing the source for each KPI:

• Volume and customer metrics → usually in the earnings press release.
• Margin and accounting-quality signals → often only fully visible in the 10-Q or 10-K.
• Real-world demand → sometimes best tracked outside the filings entirely, in third-party consumption or market-share data.

If you only ever read the press release, you're monitoring the half of the story management wanted you to see.

Separate a broken thesis from a falling price

This is the hardest discipline, and the most valuable.

When a stock you own drops sharply, there are really only two explanations. Either the business deteriorated — growth stalled, margins cracked, the story genuinely broke — or the business is fine and the valuation compressed, meaning the market simply decided to pay less for the same earnings.

These look identical on the chart and could not be more different for your decision. A thesis that broke is a reason to sell. A multiple that compressed while the business kept performing is often the opposite — it's the moment your original argument got cheaper.

History is full of examples of high-quality companies whose shares fell hard not because anything broke inside the business, but because the market re-rated what it was willing to pay — often when interest rates rose. The business kept compounding. Investors who monitored the price panicked; investors who monitored the thesis saw their claims still holding and acted accordingly.

The only way to tell the two apart in the moment is to have those pre-registered KPIs sitting in front of you. If the numbers still clear your thresholds, a falling price is noise. If they don't, the price is finally telling you something true.

Review on a schedule tied to catalysts, not emotions

The last piece is cadence. Don't check when you're anxious — check when there's new information.

For most stocks, the natural rhythm is quarterly earnings, plus any scheduled event that could move a specific KPI: an investor day, a product launch, a regulatory decision, a monthly consumption-data release. Build your review around those dates. Between them, resist the urge to re-litigate a position just because the market had a bad week.

A thesis you re-examine every time the price moves isn't a thesis — it's a mood.

Doing this across a whole portfolio is the hard part

The framework is simple. The execution is tedious. For a single stock, you can track four or five KPIs by hand, dig through the 10-Q when it files, and remember which threshold you set. For a portfolio of a dozen names, each with its own claims, its own metrics, its own filing schedule and data sources, it becomes a real job — and the moment it gets tedious is the moment most people quietly stop doing it.

That's the problem StockDashes is built to solve. Instead of you remembering to check each filing and re-deriving what changed, the dashboard keeps the numbers that matter for the stocks you own in one place and surfaces what's new — so monitoring your thesis takes minutes a quarter instead of an afternoon of digging. The goal isn't more information. It's the right information, tied to the argument you actually made when you bought.

Because in the end, the decision to hold or sell should never come down to how the chart looked this morning. It should come down to one question: is the thesis still true?

If you found this useful, you might also like our post on whether your portfolio is really diversified — another case where the obvious signal and the real one aren't the same thing.